Scottish Medicines Consortium approves four medicines for NHS use

Roche’s early stage breast cancer treatment, Pertuzumab, hasbeen accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland. The drug is used in combination with Trastuzumab and chemotherapy to treat a particular type of early stage breast cancer before surgery, and was accepted after consideration through SMC’s Patient and Clinician Engagement

Continue Reading

Roche’s drug Alecensa given approval by EC for treatment for lunch cancer patients

The European Commission has approved Roche’s Alecensa as a second-line therapy for patients with ALK-positive non-small cell lung cancer (NSCLC). The decision was based on the results of two phase II studies, which showed that Alecensa shrank tumours in up to 52.2% of patients whose disease had progressed after treatment with Pfizer’s Xalkori, which is

Continue Reading

FDA expands scope of ovarian cancer drug

The US Food and Drug Administration has approved Roche-group Genentech’s application to market Avastin for patients with a specific type of ovarian cancer. The drug has been cleared for use, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, to treat patients with platinum-sensitive recurrent

Continue Reading

Roche and Genentech receive priority review of MS drug from FDA

US regulators are conducting a priority review of Roche/Genentech’s experimental multiple sclerosis therapy Ocrevus, which some believe has the potential to transform treatment of the disease. Ocrevus is an investigational, humanised monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell, that is believed to be a key contributor to

Continue Reading

Roche’s Cancer Immunotherapy Atezolizumab gains FDA Priority Review for Advanced Bladder Cancer

Roche Group announced today that the FDA has accepted the company’s Biologics License Application (BLA) and granted Priority Review for atezolizumab for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who had disease progression during or following platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of

Continue Reading